Download PDF
Semin Respir Crit Care Med 2001; 22(5): 533-540
DOI: 10.1055/s-2001-18425
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Lung Transplantation for Pulmonary Hypertension

Sean P. Gaine1 , Jonathan B. Orens2
  • 1Mater Private Hospital, Dublin, Ireland
  • 2Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland
Further Information

Publication History

Publication Date:
14 November 2001 (online)

    Permissions and Reprints

ABSTRACT

Although lung transplantation is a viable option for patients with end-stage pulmonary hypertension, it is associated with numerous problems including infection, rejection, and limited long-term survival. Because of these limitations, transplantation should only be considered for patients who are failing maximal medical therapy. Treatment options for patients with pulmonary hypertension that may serve to prolong or obviate the need for transplantation include anticoagulation with warfarin, diuretics, and vasodilators such as calcium channel blockers or continuous intravenous epoprostenol (prostacyclin). The response to medical therapy should be assessed at regular intervals by evaluating exercise tolerance and hemodynamic parameters. Because waiting periods for transplantation now exceed 1.5 to 2 years in the United States, and the response to medications is unpredictable, referral for transplantation should occur when patients become symptomatic. Those who are responding well to medical therapy should be removed from the active transplant waiting list, whereas those who fail therapy should go on to transplant. Utilizing medical therapy and transplantation as complementary treatments will achieve the best potential to improve quality of life and prolong survival.

KEYWORD

Lung transplantation - prostacyclin - pulmonary hypertension

REFERENCES

  • 1 Reitz B A, Wallwork J L, Hunt S A. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.  N Engl J Med . 1982;  306 557-564
    CrossrefPubMedGoogle Scholar
  • 2 Rubin, L J, Nicod P, Hillis L D. Treatment of primary pulmonary hypertension with nifedipine.  Ann Intern Med . 1983;  99 433-438
    PubMedGoogle Scholar
  • 3 Rich S, Brundage B H. High dose calcium channel blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary artery pressure and regression of right ventricular hypertrophy.  Circulation . 1987;  76 135-141
    CrossrefPubMedGoogle Scholar
  • 4 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.  N Engl J Med . 1992;  327(2) 76-81
    CrossrefPubMedGoogle Scholar
  • 5 Rubin L J, Mendoza J, Hood M. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial.  Ann Intern Med . 1990;  112 485-491
    CrossrefPubMedGoogle Scholar
  • 6 Higenbottam T W, Wells F, Wheeldon D. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).  Lancet . 1984;  1 1046-1047
    PubMedGoogle Scholar
  • 7 Conte J V, Gaine S P, Orens J B. Continuous intravenous prostacyclin as a bridge to lung transplantation.  J Heart Lung Transplant . 1998;  17 679-685
    PubMedGoogle Scholar
  • 8 Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation?.  Am J Cardiol . 1995;  75(3) 63A-66A
    CrossrefPubMedGoogle Scholar
  • 9 Gaine S, Rubin L. Medical and surgical treatment options for pulmonary hypertension.  Am J Med Sci . 1998;  315(3) 179-184
    PubMedGoogle Scholar
  • 10 Rich S. Executive summary of the World Symposium on PPH. Available at: http:www.who.int/ncd/cvd/pph.html. Accessed December 2000
    Google Scholar
  • 11 Holcomb B W, Loyd J E, Ely E W. Pulmonary veno-occlusive disease: a case series and new observations.  Chest . 2000;  118(6) 1671-1679
    CrossrefPubMedGoogle Scholar
  • 12 Moser K M, Daily P O, Peterson K. Thromboendarterectomy for chronic, major vessel thromboembolic pulmonary hypertension: immediate and long-term results in 42 patients.  Ann Intern Med . 1987;  107 560-565
    PubMedGoogle Scholar
  • 13 Rubin L J. Primary pulmonary hypertension.  N Engl J Med . 1997;  336(2) 111-117
    CrossrefPubMedGoogle Scholar
  • 14 Hopkins W E, Ochoa L L, Richardson. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.  J Heart Lung Transplant . 1996;  15(1 Pt 1) 100-105
    PubMedGoogle Scholar
  • 15 D'Alonzo G E, Barst R J, Ayres S M. Survival in patients with primary pulmonary hypertension: results from a national prospective registry.  Ann Intern Med . 1991;  115(5) 343-349
    PubMedGoogle Scholar
  • 16 Rich S, Levy P S. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension.  Am J Med . 1984;  76 573-578
    CrossrefPubMedGoogle Scholar
  • 17 Rich S, Dantzker D R, Ayres S M. Primary pulmonary hypertension: a national prospective study.  Ann Intern Med . 1987;  107(2) 216-223
    CrossrefPubMedGoogle Scholar
  • 18 Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation.  J Heart Lung Transplant . 1997;  16(3) 313-319
    PubMedGoogle Scholar
  • 19 Fuster V, Steele P M, Edwards W D. Primary pulmonary hypertension: natural history and the importance of thrombosis.  Circulation . 1984;  70 580-587
    CrossrefPubMedGoogle Scholar
  • 20 Barst R J, Rubin L J, McGoon M D. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.  Ann Intern Med . 1994;  121(6) 409-415
    CrossrefPubMedGoogle Scholar
  • 21 Shapiro S M, Oudiz R J, Cao T. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoerostenol infusion.  JACC . 1997;  30(2) 343-349
    CrossrefPubMedGoogle Scholar
  • 22 Gaine S. Pulmonary Hypertension.  JAMA . 2000;  284 3160-3168
    CrossrefPubMedGoogle Scholar
  • 23 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial.  Ann Intern Med . 1980;  93 391-398
    PubMedGoogle Scholar
  • 24 Barst R J, Rubin L J, Long W A. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.  N Engl J Med . 1996;  334(5) 296-302
    CrossrefPubMedGoogle Scholar
  • 25 Badesch D B, Tapson V F, Mcgoon M D. A comparison of continuous intravenous epoprostenol with conventional therapy for pulmonary hypertension secondary to the scleroderma spectrum of diseases.  Ann Intern Med . 2000;  132(6) 425-434
    PubMedGoogle Scholar
  • 26 Kuo P C, Johnson L B, Plotkin J S. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.  Transplantation . 1997;  63(4) 604-606
    CrossrefPubMedGoogle Scholar
  • 27 Robbins I M, Gaine S P, Schilz R. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.  Chest . 2000;  117(1) 14-18
    CrossrefPubMedGoogle Scholar
  • 28 McLaughlin V V, Genthner D E, Panella M M. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.  Ann Intern Med . 1999;  4(130[9]) 740-743
    PubMedGoogle Scholar
  • 29 Rosenzweig E, Kerstein D, Barst R. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation . 1999;  13(99[14]) 1858-1865
    PubMedGoogle Scholar
  • 30 Sandoval J, Gaspar J, Pulido T. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients nonresponsive to vasodilator treatment.  J Am Coll Cardiol . 1998;  32(2) 297-304
    CrossrefPubMedGoogle Scholar
  • 31 Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension.  Am J Coll Cardiol . 1983;  51 1560-1561
    CrossrefPubMedGoogle Scholar
  • 32 Kerstein D, Levy P S, Hsu D T. Blade balloon atrial septostomy improves survival in patients with severe primary pulmonary hypertension.  Circulation . 1995;  91(7) 2028-2035
    PubMedGoogle Scholar
  • 33 Rothman A, Sklansky M S, Lucas V W. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension.  Am J Cardiol . 1999;  15(84(6)) 682-686
    PubMedGoogle Scholar
  • 34 Rothman A, Beltran D, Kriett J M. Graded balloon dilation atrial septostomy as a bridge to lung transplantation in pulmonary hypertension [see comments].  Am Heart J . 1993;  125(6) 1763-1766
    CrossrefPubMedGoogle Scholar
  • 35 Tarver J H, Rosas I, Diette G B. Chronic ambulatory dopamine infusion therapy for refractory right heart failure due to pulmonary hypertension.  ARRCM . 2000;  161(3) A459
    PubMedGoogle Scholar
  • 36 UNOS data. Available at: http://www.unos.org/frame_default.asp. Accessed October 2001
    Google Scholar
  • 37 Lilienfeld D, Rubin L. Mortality from primary pulmonary hypertension in the United States, 1979-1996.  Chest . 2000;  117(3) 796-800
    CrossrefPubMedGoogle Scholar
  • 38 Maurer J R, Frost A E, Estenne M. International guidelines for the selection of lung transplant candidates.  J Heart Lung Transplant . 1998;  17(7) 703-709
    PubMedGoogle Scholar
  • 39 Whyte R I, Robbins R C, Altinger J. Heart-lung transplantation for primary pulmonary hypertension.  Ann Thorac Surg . 1999;  67(4) 937-942
    CrossrefPubMedGoogle Scholar
  • 40 Bando K, Keenan R J, Paradis I L. Impact of pulmonary hypertension on outcome after single-lung transplantation.  Ann Thorac Surg . 1994;  58(5) 1336-1342
    CrossrefPubMedGoogle Scholar
  • 41 Bando K, Armitage J M, Paradis I L. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension.  J Thorac Cardiovasc Surg . 1994;  108(6) 1056-1065
    PubMedGoogle Scholar
  • 42 Pasque M K, Trulock E P, Cooper J D. Single lung transplantation for pulmonary hypertension: single institution experience in 34 patients.  Circulation . 1995;  92 2252-2258
    CrossrefPubMedGoogle Scholar
  • 43 Hosenpud J D, Bennett L E, Keck B M, Boucek M M, Novick R J. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000.  J Heart Lung Transplant . 2000;  19 909-931
    CrossrefPubMedGoogle Scholar
  • 44 Levine S MJ, Erikinson S G, Bryan C L. Ventilation-perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension.  Chest . 1992;  101 401-405
    CrossrefPubMedGoogle Scholar
  • 45 1999 Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data: 1989-1998. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation; Richmond, VA: UNOS
    Google Scholar
  • 46 Hosenpud J D, Bennett L E, Keck B M. The Registry of the International Society for Heart and Lung Transplantation: fourteenth official report-1997.  J Heart Lung Transplant . 1997;  16 691-712
    PubMedGoogle Scholar
      >